DIXDC1 contributes to psychiatric susceptibility by regulating dendritic spine and glutamatergic synapse density via GSK3 and Wnt/β-catenin signaling

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Martin, P., R. E. Stanley, A. P. Ross, A. E. Freitas, C. E. Moyer, A. C. Brumback, J. Iafrati, et al. 2016. "DIXDC1 contributes to psychiatric susceptibility by regulating dendritic spine and glutamatergic synapse density via GSK3 and Wnt/β-catenin signaling." Molecular psychiatry :10.1038/mp.2016.184. doi:10.1038/mp.2016.184. http://dx.doi.org/10.1038/mp.2016.184.

Published Version
doi:10.1038/mp.2016.184

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:32630523

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
**DIXDC1** contributes to psychiatric susceptibility by regulating dendritic spine and glutamatergic synapse density via GSK3 and Wnt/β-catenin signaling

Pierre-Marie Martin#1, Robert E. Stanley#1,2, Adam P. Ross#1, Andiara E. Freitas#1, Caitlin E. Moyer3, Audrey C. Brumback1,4, Jillian Iafrati1, Kristina S. Stapornwongkul1, Sky Dominguez1, Saul Kivimäe1, Kimberly A. Mulligan1,5, Mehdi Pirooznia6, W. Richard McCombie7, James B. Potash8, Peter P. Zandi9, Shaun M. Purcell10, Stephan J. Sanders1,11, Yi Zuo3, Vikaas S. Sohal1,11,12, and Benjamin N.R. Cheyette1,2,11,12

1Department of Psychiatry, University of California San Francisco, San Francisco CA, 94143, USA (UCSF)

2TETRAD Graduate Program, UCSF

3Department of Molecular, Cell and Developmental Biology, University of California Santa Cruz, Santa Cruz CA, 95064, USA.

4Department of Neurology, Division of Child Neurology, UCSF

6Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical Institutions, Baltimore MD, 21287, USA

7Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, Woodbury, NY 11797, USA

8Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA, 52242, USA

9Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA

10Departments of Psychiatry, Massachusetts General Hospital & Harvard Medical School, Boston MA 02114, USA

11UCSF Weill Institute for Neurosciences, UCSF

12Kavli Institute for Fundamental Neuroscience, UCSF

# These authors contributed equally to this work.

**Abstract**

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

Contact information. bc@ucsf.edu.

Conflict of interest. The authors declare no conflict of interest.
Mice lacking DIX domain containing-1 (DIXDC1), an intracellular Wnt/β-catenin signal pathway protein, have abnormal measures of anxiety, depression and social behavior. Pyramidal neurons in these animals’ brains have reduced dendritic spines and glutamatergic synapses. Treatment with lithium or a Glycogen Synthase Kinase-3 (GSK3) inhibitor corrects behavioral and neurodevelopmental phenotypes in these animals. Analysis of DIXDC1 in over 9,000 cases of autism, bipolar disorder and schizophrenia reveals higher rates of rare inherited sequence-disrupting single nucleotide variants (SNVs) in these individuals compared to psychiatrically-affected controls. Many of these SNVs alter Wnt/β-catenin signaling activity of the neurally-predominant DIXDC1 isoform; a subset that hyperactivate this pathway cause dominant neurodevelopmental effects. We propose that rare missense SNVs in DIXDC1 contribute to psychiatric pathogenesis by reducing spine and glutamatergic synapse density downstream of GSK3 in the Wnt/β-catenin pathway.

Introduction

Advances in human genomics are revolutionizing knowledge of molecules conferring susceptibility to psychiatric disorders, but have simultaneously highlighted the complexity of genetic contributions and underscored a need to define common biological pathways. One pathway proposed to play a role based on such evidence is Wnt/β-catenin signaling, a biochemical cascade conserved in all metazoans by which nearby cells communicate during and after development.

DIX Domain Containing 1 (DIXDC1), a positive cytoplasmic transducer of the Wnt/β-catenin pathway, is of additional interest because it interacts with Disrupted in Schizophrenia 1 (DISC1), a gene separately implicated in the genetics of psychiatric disorders including schizophrenia (Scz), major depression, bipolar disorder (BD) and ASD. Compared to some core Wnt/β-catenin pathway components, DIXDC1 has a relatively restricted tissue distribution including in the late developmental and postnatal central nervous system, suggesting that it might have specialized roles in neurons and that its functional sequence variants might manifest as behavioral syndromes in the human population.

Here we describe a multifaceted analysis of DIXDC1 in neurodevelopment and psychopathogenesis. Using behavioral, neurodevelopmental, biochemical and pharmacological analyses of a knock-out mouse model combined with human genetic analyses across several psychiatric disorders and functional analyses of rare missense mutations found in one set of such patients (ASD), we show that DIXDC1 participates in the regulation of dendritic spine and glutamatergic synapse density downstream of Wnt/β-catenin signaling and upstream of behavior, particularly depression- and anxiety-like behaviors potentially relevant to affective disorders and reciprocal social interactions potentially relevant to ASD.
Materials and Methods

Animals

The Dixdc1 knock-out (Dixdc1KO) mouse line was created by gene-targeting that replaced several critical exons of the Dixdc1 locus with a neo interrupter cassette, causing loss of Dixdc1 gene products confirmed at both the mRNA and protein levels (Supplementary Figure 1a). Products of the original gene-targeting event were outcrossed >10 times to different wild type (WT) mice to eliminate flanking allele effects, and mice for this study were maintained in an outbred mixed (~75% CD-1; Charles River) genetic background. All comparisons were made in cohorts of littermate mice, separated by genotype blind to experimenter.

Statistical analysis

Data were analyzed by Student’s t-test, 2-way ANOVA followed by multiple comparisons, Chi square or Fisher’s exact test using GraphPad Prism software (GraphPad Software, La Jolla, CA, USA) and are displayed as mean ± s.e.m. Variance was similar between all groups compared; all reported differences minimally reflect significance of p ≤0.05 for experimental vs. control.

Details are provided in Supplementary Materials and Methods.

Results

Depression, anxiety and social behavior in Dixdc1KO mice

We showed previously that homozygous Dixdc1KO mice maintained in an isogenic C57Bl/6 background had behavioral differences potentially relevant to psychiatry, but were also generally hypoactive.(10) Neurodevelopmental and behavioral phenotypes in mice can be sensitive to isogenic background and this has occasionally confounded interpretation.(11-13) Accordingly, we reprobed Dixdc1KO mice for behavioral and neurodevelopmental phenotypes that remained robust even in a mixed outbred (primarily CD-1) genetic background and used these mice for all behavioral and neurodevelopmental phenotyping in this study.

Outbred Dixdc1KO mice were no different from WT littermates in general activity or several other behavioral measures (Supplementary Table 1), yet had decreased latency to immobility (Figure 1a, left) and spent more total time immobile (Figure 1a, right) in the Forced Swim Test (FST), an assay for behavioral despair regarded as a rodent model for depression.(14) These mice also had a trend toward increased total time immobile in the tail suspension test, an independent assay for behavioral despair (Supplementary Figure 2). Homozygous Dixdc1KO mice also spent less time than WT littermates in the center versus surround of an open field (Figure 1b), an indication of increased anxiety.(15) Furthermore, in the hyponeophagia assay which measures balance between opposing drives to feed versus to avoid the unfamiliar,(16) Dixdc1KO mice had an increased latency to begin feeding (Figure 1c left) and spent less total time feeding (Figure 1c right).
In the social interactions in pairs test (SIP), where 2 males of the same genotype freely interact within a closed arena,(17) Dixdc1KO mice spent less time together than WT littermates (Figure 1d, left). Interestingly, this decrease in total interaction time was not attributable to reduced number of mouse-mouse interactions. Instead Dixdc1KO mice spent less time on average during each interaction (Figure 1d, middle) and their longest interaction time was shorter (Figure 1d, right). Interactions of longer duration in this assay were characterized by reciprocal social behavior including nose-to-nose sniffing, nose-to-anogenital sniffing, or one animal following close behind the other, suggesting that reciprocal social interactions are deficient in this mouse model.

Pyramidal neurons in Dixdc1KO mice have reduced spines and glutamatergic synapses

Dixdc1KO mice are viable and fertile and have grossly normal brains with typical regional architecture(10) (Supplementary Figure 1b-h). We therefore searched for other neuronal phenotypes underlying behavioral differences in these animals. Studies of other neurodevelopmentally-expressed Wnt pathway components and DISC1 have supported roles in dendrite, dendritic spine and glutamatergic synapse formation and function.(18-22) To initially probe for these phenotypes in the Dixdc1KO mouse line, we employed cultured hippocampal neurons because of their established validity for modeling these aspects of neurodevelopment.(22) Both visual inspection and Sholl analysis (23) revealed no significant differences in dendrite arborization in neurons from Dixdc1KO neonates in the mixed outbred genetic background (Supplementary Figure 3a-c); however mutant neurons had significantly reduced spine density along primary dendrites (Figure 1e and f) and a significantly increased percentage of immature (filopodial) spines (Figure 1e and g). We confirmed these same spine phenotypes within forebrain cortical tissue by crossing in transgenic Thy1-GFP alleles that sparsely label deep layer (L5/6) pyramidal neurons(24), then collecting tissue and quantifying density and maturity of spines along apical dendrites of individual GFP-expressing neurons(18); here again Dixdc1KO mutants had reduced spine density and an increased percentage of filopodial spines (Figure 1h-j). In the living brain, we imaged apical dendrites and spines in one-month-old transgenic Thy1-YFP mice using transcranial two-photon imaging, once more finding that spine density on L5 apical dendrites in the somatosensory cortex was reduced in the Dixdc1KO (Figure 1k and l). Interestingly, spine dynamics (proportion of spines formed and eliminated over 7 days) were no different between Dixdc1KO and WT littermates at this stage (Figure 1m). To functionally substantiate imaging findings, we conducted internal electrophysiological recordings from L5/6 corticothalamic pyramidal neurons in the prefrontal cortex. In Dixdc1KO mice these neurons had a reduced hyperpolarization-activated cationic current (h-current; \( I_h \)) as estimated from the reduction in voltage “sag” and rebound after-depolarization (ADP) in response to a hyperpolarizing current pulse (Figure 1n and o). We confirmed this by directly measuring \( I_h \) current in response to hyperpolarizing voltage steps: this current was reduced in Dixdc1KO L5/6 corticothalamic pyramidal neurons and inhibited by the \( I_h \) channel blocker ZD7288 (Figure 1p and q). The \( I_h \) current is mediated by hyperpolarization-activated cyclic nucleotide-gated (HCN) channels localized primarily to mature spines.(25) We therefore corroborated the electrophysiological finding of reduced \( I_h \) current via the methodologically-independent strategy of fluorescent immunohistochemistry, visualizing the HCN1 channel protein using a specific antibody and counting puncta along...
dendrites of GFP-expressing L5/6 pyramidal neurons in Thy1-GFP mice. This method confirmed a significant reduction in HCN1 puncta on Dixdc1KO L5/6 pyramidal neuron dendrites (Figure 1r and s). In sum, the electrophysiological and immunohistochemical data agree and strongly support our other measures of reduced mature spine density in these animals.

Spines correspond to the postsynaptic compartment of most glutamatergic inputs to pyramidal neuron dendrites.(26) We therefore asked whether spine deficits in Dixdc1KO pyramidal neurons were accompanied by deficits in glutamatergic synapse density. Cultured neurons from Dixdc1KO neonates had reduced glutamatergic synapse density along dendrites as measured by fluorescent confocal colocalization of pre- and post-synaptic molecular markers (Figure 1t and u). We confirmed this within cortical tissue, observing a deficit in glutamatergic synapse density along apical dendrites of individual pyramidal neurons in Thy1-GFP Dixdc1KO mice (Figure 1v and w). In contrast, using similar methodologies we detected no differences in GABAergic synapse density (Supplementary Figure 3d-g).

Neurons from Dixdc1KO mice have impaired Wnt/β-catenin signal transduction

Given that Dixdc1 has a conserved subdomain that directly interacts with the core Wnt/β-catenin pathway components Dvl and Axin,(5, 6, 27, 28) we hypothesized that Wnt/β-catenin signal transduction would be impaired at the level of these cytoplasmic signal transduction proteins in differentiating Dixdc1KO pyramidal neurons. We tested this via several complementary approaches: First we tested whether Wnt/β-catenin signal pathway activity was altered in developing neurons of Dixdc1KO mice by directly measuring levels of β-catenin unphosphorylated at residue S33 (“active β-catenin”); the molecular target of GSK3 in the Wnt/β-catenin pathway. There was no difference in levels of active β-catenin in unstimulated Dixdc1KO versus WT cultured forebrain neurons (Figure 2a and b). However, treatment of these neurons with Wnt3a, an extracellular activator of this pathway,(29) resulted in markedly different responses in Dixdc1KO versus WT: In WT the level of active β-catenin rose markedly in response to Wnt3a, indicating Wnt/β-catenin signal transduction via regulation of GSK3-mediated phosphorylation (Figure 2a and c). Contrastingly, in Dixdc1KO neurons there was no effect of Wnt3a treatment on active β-catenin level (Figure 2a and c). Because GSK3 is independently regulated by the AKT pathway, we asked whether markers for this pathway were altered in Dixdc1KO versus WT neurons. In contrast to deficiencies observed in Wnt/β-catenin signal transduction, there were no differences in biochemical markers for the AKT pathway, including levels of phosphorylated AKT (p-AKT(Ser473)) or its specifically phosphorylated targets GSK3 (p-GSK3α(Ser21) and p-GSK3β(Ser9)) and β-catenin (p-β-cat(Ser522)) in Dixdc1KO neurons (Figure 2d).

The most universal transcriptional targets of the Wnt/β-catenin pathway are Axin2 and its molecular relative Axin1. We confirmed Wnt/β-catenin signal pathway disruption in Dixdc1KO neurons by directly measuring levels of these transcriptional targets using the quantitative reverse-transcriptase polymerase chain reaction (Q-PCR). There was no difference in mRNA levels of Axin1 or Axin2 in unstimulated Dixdc1KO versus WT cultured forebrain neurons (Figure 2e-g), demonstrating that these targets are basally
transcribed normally in Dixdc1KO neurons. As expected, recombinant expression of a point-mutant-stabilized form of β-catenin (β-cat(S33Y)) that bypasses Wnt signal transduction increased Axin1 and Axin2 transcription in both Dixdc1KO and WT neurons with no effect on the control GAPDH transcript (Figure 2e-g). In contrast, treatment with Wnt3a resulted in markedly different responses in Dixdc1KO versus WT neurons: levels of both target transcripts rose markedly in WT, whereas this signaling response was greatly attenuated in Dixdc1KO neurons (Figure 2e and f).

To determine whether dendritic spine and glutamatergic synapse phenotypes arise from decreased Wnt/β-catenin signaling efficiency in Dixdc1KO pyramidal neurons, we sought to rescue neurodevelopmental phenotypes by stimulating the pathway upstream and downstream of the putative pathway block. As anticipated, treatment with the upstream ligand Wnt3a had no or minimal effect on spine maturity and glutamatergic synapse density although it did partially rescue spine density in Dixdc1KO cultured hippocampal neurons (Figure 2h-j, right-most bars). In contrast, bypassing the pathway via transfection with β-cat(S33Y) rescued all these phenotypes (Figure 2h-j, middle bars). Interestingly, recombinant expression of β-cat(S33Y) in WT neurons also significantly decreased spine and synapse density (‘#’ in Figure 2h, j). These data suggest that either Wnt/β-catenin pathway hyperactivity or hypoactivity during neural differentiation can lead to grossly similar spine and glutamatergic synapse reductions.

**Behavioral and neurodevelopmental phenotypes are rescued by lithium or GSK3 inhibitor**

Supporting a strong genotype-phenotype correlation between the Dixdc1KO allele and behavioral phenotypes in the Dixdc1KO mouse line, we noticed that behavioral differences on the FST, hyponeophagia assay and SIP were gene-dose sensitive, with heterozygous Dixdc1KO mice displaying an intermediate phenotype (Figure 1a, c and d, grey bars). We hypothesized that this reflects Dixdc1-dose-sensitive reductions in Wnt/β-catenin signal transduction. To test this hypothesis, we asked whether these behavioral phenotypes could be corrected by treatment with the mood stabilizing agent lithium chloride, which among other cell biological effects activates the Wnt/β-catenin pathway through direct inhibition of GSK3.(30) Indeed, systemic injection of either lithium chloride or a selective small molecule GSK3 inhibitor (GSK3i) corrected behavioral phenotypes in Dixdc1KO animals, including in the FST (Figure 3a) and SIP (Figure 3b). Combined with reversible pharmacology (Supplementary Figure 4), these data support that behavioral phenotypes in this animal model occur secondary to Dixdc1 gene-dose sensitive changes in the regulation of GSK3, specifically increased GSK3 activity.

We hypothesized that lithium/GSKi-responsive behavioral abnormalities in Dixdc1KO mice correspond to spine and glutamatergic synapse deficits and tested this by using a drug administration protocol identical to that which rescued behavior, assessing neurodevelopmental phenotypes instead. We found that both lithium and GSK3i rescued dendritic spine density, spine morphology and glutamatergic synapse density in L5/6 pyramidal neurons within these animals’ brains (Figure 3c-k).
Inherited rare missense DIXDC1 SNVs are more prevalent in psychiatric cases

Given the preceding results, we asked whether sequence variation at the DIXDC1 locus, which encodes two major isoform classes (Figure 4a)(6, 31), might contribute to psychiatric disorders. We first analyzed two datasets of exome sequences (Supplementary Figure 5), totaling nearly 6000 ASD cases and over 7000 controls, focusing on ‘sequence-disrupting’ SNVs most likely to affect Dixdc1 function: i.e. nonsense, missense and conserved splice-donor/acceptor-disrupting SNVs. This revealed a greater burden of rare sequence-disrupting SNVs at this locus in ASD versus unaffected controls (Figure 4b and c, left-most bars; Supplementary Figure 5a and b).

Next, we analyzed a sample of approximately 1000 BD patients and a similarly sized ethnically-matched control cohort. There was once again a greater burden of rare sequence-disruptive SNVs in both isoforms in BD cases versus controls (Figure 4b and c, middle-left bars). Finally, we analyzed a dataset of over 2500 exome sequences from Scz patients and a similar number of ethnically-matched controls.(32) Here again, a greater burden of rare sequence-disruptive SNVs was present in cases versus controls (Figure 4b and c, middle-right bars).

In each psychiatric dataset (2 ASD datasets, 1 BD dataset and 1 Scz dataset) there was a higher burden of rare sequence-disrupting SNVs in each of two major DIXDC1 isoforms in those affected, compared to those unaffected, by the disorder. Combining these datasets - totaling over 9000 cases and over 11000 controls – there was a higher burden of rare sequence-disruptive SNVs for each isoform across these three psychiatric disorders; this association was greater for isoform 2 than for isoform 1 (isoform 1, \( p=1.7\times10^{-3}\); isoform 2, \( p=2\times10^{-4}\); Figure 4b and c, right-most bars; Supplementary Tables 2 and 3).

Rare missense SNVs from ASD patients alter Wnt/\(\beta\)-catenin signaling function

The two major DIXDC1 isoforms have distinct expression patterns, the longer isoform 1 has a relatively widespread embryonic tissue distribution, whereas the shorter isoform 2 predominates in the developing nervous system at later stages and in neurons of the mature brain.(6, 9, 33) Isoform 2 also has far more robust activity in standard cell-based Wnt/\(\beta\)-catenin signaling assays (Figure 4d).(6) We accordingly tested rare missense SNVs in isoform 2 from our discovery dataset (Fig 5a and Supplementary Table 3, AASC) for functional effects on this pathway by engineering each SNV into a human DIXDC1 isoform 2 cDNA and testing signaling activity.(34) We found that, compared to WT, most of these SNVs either reduced or increased Wnt/\(\beta\)-catenin pathway activation by the encoded protein (Figure 5b).

Rare Missense SNVs from Psychiatric Patients Fail to Rescue Spine and Synapse Deficits

To confirm functional conservation between the mouse and human DIXDC1 proteins, we tested whether WT human DIXDC1 could rescue neurodevelopmental phenotypes in Dixdc1KO cultured hippocampal neurons by recombinantly expressing the WT human isoform 2 protein beginning at 12 days in vitro (DIV12), assessing neurodevelopmental phenotypes 6 days later (DIV18). WT human isoform 2 completely rescued spine density,
spine maturity and glutamatergic synapse density in Dixdc1KO neurons (Figure 5c-e, grey bar).

Given our phenotypic data in the Dixdc1KO animal model, we hypothesized that rare sequence-disrupting SNVs discovered in psychiatric patients might alter Wnt/β-catenin signal transduction upstream of effects on spine and glutamatergic synapse density. To test this, we assessed SNV-containing cDNAs for their ability to rescue Dixdc1KO neurodevelopmental phenotypes similar to the WT protein. Isoform 2 cDNAs containing control-derived SNVs (K89I and C389F) rescued neurodevelopmental phenotypes in cultured neurons much like the WT protein (Figure 5c-e, blue bars). Remarkably, no cDNAs containing SNVs found in the ASD cases rescued these neurodevelopmental phenotypes (Figure 5c-e, red bars).

**Wnt/β-catenin pathway hyperactivating SNVs cause dominant spine and synapse deficits**

With allele frequencies $\leq 0.1\%$, each of the SNVs we studied is present in a single copy in patients; to contribute to psychiatric pathogenesis they must therefore have a dose-dependent or dominant effect over the WT allele. To test for this, we assessed whether SNV-containing isoform 2 cDNAs caused dominant neurodevelopmental effects when recombinantly expressed in WT cultured hippocampal neurons. The WT human isoform 2 protein had no effect on spine density, spine maturity or glutamatergic synapse density when recombinantly expressed in WT neurons (Figure 5f-h, grey bar). Similarly, no isoform 2 cDNAs encoding Wnt/β-catenin pathway hypoactivating or neutral SNVs, whether found in our control samples (K89I and C389F) or our ASD samples (R154T, R249Q, T401M and P285T), had dominant effects on neurodevelopment (Figure 5f-h, blue, left and middle red bars). In contrast, all the Wnt/β-catenin pathway hyperactivating SNVs (A87T, Q169R, K188N, Q218H and R367W) had dominant neurodevelopmental effects - i.e. decreased spine density, increased immature spine percentage and decreased glutamatergic synapse density (Figure 5f-h, right red bars).

**Discussion**

Several lines of evidence reported here support that altered Wnt/β-catenin signaling generates neurodevelopmental and behavioral phenotypes in Dixdc1KO mice and contributes to neurodisruptive effects of rare DIXDC1 sequence variants in human psychiatric patients. First, rare DIXDC1 missense SNVs found in psychiatric patients interfere with the protein’s Wnt/β-catenin signaling function *in vitro*. Second, a subset of SNVs that hyperactivate the Wnt/β-catenin pathway cause dominant neurodevelopmental effects on spine and synapse density, whereas SNVs that do not hyperactivate the pathway do not cause dominant effects. Third, Wnt/β-catenin signaling hypoactivity is associated with similar neurodevelopmental and gene-dose-sensitive behavioral phenotypes in a Dixdc1KO mouse model. Fourth, pharmacologically mimicking pathway activation via direct inhibition of GSK3, whether by the psychiatric drug lithium chloride or a selective small molecule GSK3 inhibitor, corrects neurodevelopmental and behavioral phenotypes in this animal model.
Recent genomic and pharmacological studies suggest that the pathophysiology of ASD, Scz and major affective disorders overlaps and involves formation, maintenance, removal and function of spines and glutamatergic synapses.\(^1, 2, 4, 35-38\) Our findings fit into this narrative, adding further evidence that abnormal spine and glutamatergic synapse density contributes to psychiatric pathogenesis. Our work provides a compelling case that Dixdc1 contributes to the formation, plasticity and/or maintenance of dendritic spines and glutamatergic synapses via facilitation of Wnt/\(\beta\)-catenin signal transduction within pyramidal neurons and that rare missense variants in DIXDC1 contribute to psychiatric susceptibility by decreasing or increasing Wnt pathway activity in these cells. This is consistent with evidence from large-scale sequencing and other studies showing that loss-of-function mutations in either Wnt/\(\beta\)-catenin pathway inhibitors (e.g. CHD8, APC)\(^39, 40\) or activators (e.g. CTTN\(\beta\), WNT1)\(^4, 41, 42\) contribute to susceptibility for ASD, as well as identifying differentiating cortical pyramidal neurons as a likely locus of cellular pathology in this disorder.\(^43\)

Nonetheless, we cannot rule out that additional biochemical mechanisms may contribute to these neurodevelopmental and behavioral outcomes. For example, a \(\beta\)-catenin-independent mechanism downstream of GSK3, such as one that regulates cytoskeletal proteins,\(^44\) could also be important in mediating spine and synapse density. Dixdc1 isoforms have been implicated in other signaling cascades including LKB-MARK1/4,\(^45\) PI3K-AKT/AP1, \(^46-48\) CKD5-DISC1-Ndel1,\(^7\) JNK\(^49, 50\) and actin binding.\(^31\) Our studies have focused on the late neurally-enriched, Wnt/\(\beta\)-catenin-pathway active isoform of DIXDC1 for which we found the most compelling genetic evidence for association with psychiatric disorders (Figure 4b and c). It is plausible that genetic variants affecting more than one DIXDC1 isoform (Supplementary Tables 2 and 3) contribute to psychiatric susceptibility by disrupting multiple biological pathways.\(^7\)

Several different biochemical mechanisms have been proposed to underlie the anxiolytic, antidepressant and mood-stabilizing properties of lithium, a drug whose systematic use in modern psychiatry began in the first half of the last century.\(^51\) Lithium’s best-validated mechanisms of action are inhibitory effects on IMP and INPP1, central phosphatases in the phosphoinositide pathway - and on GSK3, the central kinase in the Wnt/\(\beta\)-catenin and AKT pathways.\(^52\) Our data showing that loss of Dixdc1 in mice leads to impaired neuronal Wnt/\(\beta\)-catenin signal transduction and gene-dose-sensitive behavioral phenotypes rectified by lithium or a selective GSK3 inhibitor support that GSK3 inhibition is a major contributor to lithium’s therapeutic action. Moreover, in this mouse model the correlation between GSK3, behavior, dendritic spine and glutamatergic synapse phenotypes supports the notion that spines and glutamatergic synapses are critical biological substrates underlying lithium-responsive psychiatric conditions.\(^53-55\).

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.
Acknowledgments

Supported by grants from SFARI (Grant 329269 to BC and Undergraduate Summer Research Award to SD/BC), a NARSAD Independent Investigator Award (BC), NIMH T32 #T32MH089920-05 (AR/BC) and NICHD R01 supplement R01HD55300-8 (RS/BC), Brazilian National Council for Scientific and Technological Development grant 248426/2013-3 (AP/BC), the UCSF Department of Psychiatry (BC, VS) and NIMH R01MH104227, R01MH094449 and NINDS R01NS078791 (YZ). The ARRA ASD Sequencing Collaborative provided sequence data sets accessible from dbGaP at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number phs000298.v1.p1, under dbGAP Research Project #5694: "Analysis of Wnt signaling pathway gene variants in ASD and Scz". The Bipolar Disorder Exome work was supported by NIMH R01MH087979 (JB), WRM R01MH087992 (WRM) and K01MH093809 (MP) with additional contributors: Melissa Kramer, Jennifer Parla, Eric T. Monson, Fernando S. Goes, Marie Breen and Virginia L. Willour. We thank P Minasi for technical assistance and XY Yang, G Patil, D Vogt and EL Pai for their support in the Cheyette and neighboring Rubenstein labs. Confocal microscopy was performed at the Nikon Imaging Center (California Institute for Quantitative Biosciences, University of California San Francisco, San Francisco, CA) with advice from Kurt Thorn. BC is grateful for mentorship from S. Lawrence Zipursky (UCLA) and Randall T. Moon (UW), and encouragement from David E. Krantz (UCLA), John L.R. Rubenstein (UCSF) & Samuel H. Barondes (UCSF).

References

1. Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet. May 1; 2014 94(5): 677–94. [PubMed: 24768552]
2. De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha KE, Cicek AE, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014
3. Mulligan KA, Cheyette BN. Wnt signaling in vertebrate neural development and function. J Neuroimmune Pharmacol. Dec; 2012 7(4):774–87. [PubMed: 23015196]
4. Krumm N, O’Roak BJ, Shendure J, Eichler EE. A de novo convergence of autism genetics and molecular neurosciences. Trends Neurosci. Feb; 2014 37(2):95–105. [PubMed: 24387789]
5. Shiomi K, Uchida H, Keino-Masu K, Masu M. Ccd1, a novel protein with a DIX domain, is a positive regulator in the Wnt signaling during zebrafish neural patterning. Curr Biol. Jan 8; 2003 13(1):73–7. [PubMed: 12526749]
6. Shiomi K, Kanemoto M, Keino-Masu K, Yoshida S, Soma K, Masu M. Identification and differential expression of multiple isoforms of mouse Coiled-coil-DIX1 (Ccd1), a positive regulator of Wnt signaling. Brain Res Mol Brain Res. Apr 27; 2005 135(1-2):169–80. [PubMed: 15857680]
7. Singh KK, Ge X, Mao Y, Drake L, Meletis K, Samuels BA, et al. Dixdc1 is a critical regulator of DISC1 and embryonic cortical development. Neuron. Jul 15; 2010 67(1):33–48. [PubMed: 20624590]
8. Porteous DJ, Millar JK, Brandon NJ, Sawa A. DISC1 at 10: connecting psychiatric genetics and neuroscience. Trends Mol Med. Dec; 2011 17(12):699–706. [PubMed: 22015021]
9. Soma K, Shiomi K, Keino-Masu K, Masu M. Expression of mouse Coiled-coil-DIX1 (Ccd1), a positive regulator of Wnt signaling, during embryonic development. Gene Expr Patterns. Mar; 2006 6(3):325–30. [PubMed: 16378754]
10. Kivimae S, Martin PM, Kaplhamer D, Ruan Y, Heberlein U, Rubenstein JL, et al. Abnormal behavior in mice mutant for the Disc1 binding partner, Dixdc1. Transl Psychiatry. 2011; 1:e43. [PubMed: 22832659]
11. Kivimae S, Martin PM, Kaplhamer D, Ruan Y, Heberlein U, Rubenstein JL, et al. Abnormal behavior in mice mutant for the Disc1 binding partner, Dixdc1. Transl Psychiatry. 2011; 1:e43. [PubMed: 22832659]
12. Chadman KK, Gong S, Scattoni ML, Boltuck SE, Gandhy SU, Heintz N, et al. Minimal aberrant behavioral phenotypes of neuregulin-3 R451C knockin mice. Autism Res. Jun; 2008 1(3):147–58. [PubMed: 19360662]
13. Long JM, LaPorte P, Paylor R, Wynshaw-Boris A. Expanded characterization of the social interaction abnormalities in mice lacking Dv11. Genes Brain Behav. 2004; 3(1):51–62. [PubMed: 14960015]
14. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev. 2005; 29(4-5):547–69. [PubMed: 15893822]

15. Crawley JN. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res. Jul 17; 1999 835(1):18–26. [PubMed: 10448192]

16. Deacon RM. Hyponeophagia: a measure of anxiety in the mouse. J Vis Exp. 2011; (51)

17. Jamain S, Radyushkin K, Hammerschmidt K, Granon S, Boretius S, Varoqueaux F, et al. Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. Proc Natl Acad Sci U S A. Feb 5; 2008 105(5):1710–5. [PubMed: 18227507]

18. Arguello A, Yang X, Vogt D, Stanco A, Rubenstein JL, Cheyette BN. Dapper antagonist of catenin-1 cooperates with Dishevelled-1 during postsynaptic development in mouse forebrain GABAergic interneurons. PLoS One. 2013; 8(6):e67679. [PubMed: 23826333]

19. Hall AC, Lucas FR, Salinas PC. Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell. Mar 3; 2000 100(5):525–35. [PubMed: 10721990]

20. Hayashi-Takagi A, Takaki M, Graziane N, Seshadri S, Murdoch H, Dunlop AJ, et al. Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. Nat Neurosci. Mar; 2010 13(3):327–32. [PubMed: 20139976]

21. Kerr KS, Fuentes-Medel Y, Brewer C, Barria R, Ashley J, Abruzzi KC, et al. Glial wingless/Wnt regulates glutamate receptor clustering and synaptic physiology at the Drosophila neuromuscular junction. J Neurosci. Feb 19; 2014 34(8):2910–20. [PubMed: 24553932]

22. Okerlund ND, Kivimae S, Tong CK, Peng IF, Ullian EM, Cheyette BN. Dact1 is a postsynaptic protein required for dendrite, spine, and excitatory synapse development in the mouse forebrain. J Neurosci. Mar 24; 2010 30(12):4362–8. [PubMed: 20335472]

23. Ferreira TA, Blackman AV, Oyrer J, Jayabal S, Chung AJ, Watt AJ, et al. Neuronal morphometry directly from bitmap images. Nat Methods. Oct; 2014 11(10):982–4. [PubMed: 25264773]

24. Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. Oct; 2000 28(1):41–51. [PubMed: 11086982]

25. Paspalas CD, Wang M, Arnsten AF. Constellation of HCN channels and cAMP regulating proteins in dendritic spines of the primate prefrontal cortex: potential substrate for working memory deficits in schizophrenia. Cereb Cortex. Jul; 2013 23(7):1643–54. [PubMed: 22693343]

26. Harris KM, Kater SB. Dendritic spines: cellular specializations imparting both stability and flexibility to synaptic function. Annu Rev Neurosci. 1994; 17:341–71. [PubMed: 8210179]

27. Liu YT, Dan QJ, Wang J, Feng Y, Chen L, Liang J, et al. Molecular basis of Wnt activation via the DIX domain protein Ccd1. J Biol Chem. Mar 11; 2011 286(10):8597–608. [PubMed: 21189423]

28. Luo W, Zou H, Jin L, Lin S, Li Q, Ye Z, et al. Axin contains three separable domains that confer intramolecular, homodimeric, and heterodimeric interactions involved in distinct functions. J Biol Chem. Feb 11; 2005 280(6):5054–60. [PubMed: 15579909]

29. Moon RT, Brown JD, Torres M. WNTs modulate cell fate and behavior during vertebrate development. Trends Genet. Apr; 1997 13(4):157–62. [PubMed: 9097727]

30. O’Brien WT, Klein PS. Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans. Oct; 2009 37(Pt 5):1338–8. [PubMed: 19754466]

31. Wang X, Zheng L, Zeng Z, Zhou G, Chien J, Qian C, et al. DIXDC1 isoform, l-DIXDC1, is a novel filamentous actin-binding protein. Biochem Biophys Res Commun. Aug 18; 2006 347(1):22–30. [PubMed: 16814745]

32. Purcell SM, Moran JL, Fromer M, O’Rourke D, Roussos P, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. Feb 13; 2014 506(7487):185–90. [PubMed: 24463508]

33. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. Sep 3; 2014 34(36):11929–47. [PubMed: 25186741]

Mol Psychiatry. Author manuscript; available in PMC 2017 April 19.
34. Biechele TL, Moon RT. Assaying beta-catenin/TCF transcription with beta-catenin/TCF transcription-based reporter constructs. Methods Mol Biol. 2008; 468:99–110. [PubMed: 19099249]

35. Yi F, Danko T, Botelho SC, Patzke C, Pak C, Wernig M, et al. Autism-associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons. Science. Mar 10.2016

36. Duman RS. Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci. Mar; 2014 16(1):11–27. [PubMed: 24733968]

37. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. Jan 27.2016

38. Musazzi L, Treccani G, Mallei A, Popoli M. The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors. Biol Psychiatry. Jun 15; 2013 73(12):1180–8. [PubMed: 23273725]

39. Iossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014

40. Zhou XL, Giacobini M, Anderlid BM, Anckarsater H, Omrani D, Gillberg C, et al. Association of adenomatous polyposis coli (APC) gene polymorphisms with autism spectrum disorder (ASD). Am J Med Genet B Neuropsychiatr Genet. Apr 5; 2007 144B(3):351–4. [PubMed: 17221838]

41. O’Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. May 10; 2012 485(7397):246–50. [PubMed: 22495309]

42. Martin PM, Yang X, Robin N, Lam E, Rabinowitz JS, Erdman CA, et al. A rare WNT1 missense variant overrepresented in ASD leads to increased Wnt signal pathway activation. Transl Psychiatry. 2013; 3:e301. [PubMed: 24002087]

43. Wilsey AJ, Sanders SJ, Li M, Dong S, Tebbenkamp AT, Muhle RA, et al. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell. Nov 21; 2013 155(5):997–1007. [PubMed: 24267886]

44. Ciani L, Krylova O, Smalley MJ, Dale TC, Salinas PC. A divergent canonical WNT-signaling pathway regulates microtubule dynamics: dishevelled signals locally to stabilize microtubules. J Cell Biol. 2004; 164(2):243–53. [PubMed: 14734535]

45. Goodwin JM, Svensson RU, Lou HJ, Winslow MM, Turk BE, Shaw RJ. An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential. Mol Cell. Aug 7; 2014 55(3):436–50. [PubMed: 25042806]

46. Wang L, Li H, Chen Q, Zhu T, Zhu H, Zheng L. Wnt signaling stabilizes the DIXDC1 protein through decreased ubiquitin-dependent degradation. Cancer Sci. Mar; 2009 101(3):700–6. [PubMed: 20085589]

47. Wu W, Liu Q, Liu Y, Yu Z, Wang Y. DIXdc1 targets CyclinD1 and p21 via PI3K pathway activation to promote Schwann cell proliferation after sciatic nerve crush. Biochem Biophys Res Commun. Aug 10.2016

48. Xu Z, Liu D, Fan C, Luan L, Zhang X, Wang E. DIXDC1 increases the invasion and migration ability of non-small-cell lung cancer cells via the PI3K-AKT/AP-1 pathway. Mol Carcinog. Nov; 2014 53(11):917–25. [PubMed: 23813858]

49. Ikeuchi Y, Stegmuller J, Netherton S, Huynh MA, Masu M, Frank D, et al. A SnoN-Ccd1 pathway promotes axonal morphogenesis in the mammalian brain. J Neurosci. Apr 1; 2009 29(13):4312–21. [PubMed: 19339625]

50. Wong CK, Luo W, Deng Y, Zou H, Ye Z, Lin SC. The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal kinase activation by Axin and dishevelled through distinct mechanisms. J Biol Chem. Sep 17; 2004 279(38):39366–73. [PubMed: 15262978]

51. Shorter E. The history of lithium therapy. Bipolar Disord. Jun; 2009 11(Suppl 2):4–9. [PubMed: 19538681]

52. Lenox RH, Wang L. Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol Psychiatry. Feb; 2003 8(2):135–44. [PubMed: 12610644]

53. Liu RJ, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology. Oct; 2013 38(11):2268–77. [PubMed: 23680942]
54. Kondratiuk I, Leski S, Urbanska M, Biecek P, Devijver H, Lechat B, et al. GSK-3beta and MMP-9 Cooperate in the Control of Dendritic Spine Morphology. Mol Neurobiol. Jan 6, 2016

55. Higgins GA, Allyn-Feuer A, Barbour E, Athey BD. A glutamatergic network mediates lithium response in bipolar disorder as defined by epigenome pathway analysis. Pharmacogenomics. 2015; 16(14):1547–63. [PubMed: 26343379]
Figure 1.
Phenotypes in Dixdc1KO mice. (a-d) Behavioral phenotypes. (a) Despair (FST). (b) Anxiety (time in center vs. surround in an open field). (c) Drive to eat vs. anxiety over unfamiliar (Hyponeophagia assay). (d) Social behavior (SIP). (e-s) Dendritic spine phenotypes: Primary dendrites of cultured neurons transfected with GFP (e quantified in f and g). Top, WT; bottom, KO; arrow, mature spine; asterisk, filopodial projection. Cortical L5/6 apical dendrites in brain tissue labeled by Tg(Thy1-EGFP)M (h quantified in i and j). Top, WT; bottom, KO; arrows and asterisks as in (e). (k-m) Imaging of spine density and spine dynamics in vivo. 2-photon images of the same dendritic branch over 7 days labeled by Tg(Thy1-YFP)H in the primary somatosensory cortex of living adult mice (k quantified in l and m). Top, WT; bottom, KO; arrow, eliminated spine; arrowhead, newly-formed spine. (n-q) Recording of Ih-dependent voltage and current. (n) Representative whole cell current clamp recordings in L5/6 prefrontal corticothalamic neurons; black, WT; orange, KO. (o) Quantification of voltage sag and rebound (ADP) dependent of Ih. (p) Direct measurement of hyperpolarization-activated currents and inhibition by ZD7288, a specific antagonist of Ih; black, WT; orange, KO; grey, ZD7288 treated WT; light orange, ZD7288 treated KO. (q) Ih current activation at −120mV potential step; colors as in p. (r-s) Immunohistological
visualization of HCN1 channel protein: Representative micrographs of cortical L5/6 apical dendrites (r quantified in s). Top, WT; bottom, KO; far red, HCN1; green (Tg(Thy1-EGFP)M). (t-w) Glutamatergic synapse phenotypes. Co-localized immunohistochemical markers for glutamatergic synapses on dendrites in GFP-transfected cultured neurons (t quantified in u), and cortical L5/6 apical dendrites labeled by Tg(Thy1-EGFP)M (v quantified in w). Top, WT; bottom, KO; blue, VGLUT; red, PSD95; green, GFP; arrowheads, colocalized green/blue/red puncta. Scale bars, 5 μm. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001
Figure 2.
Decreased Wnt/β-catenin signal transduction in Dixdc1KO neurons. (a) Immunoblot of active β-catenin (ABC) from cultured neurons; (b-c) Quantification in unstimulated (b) and Wnt3a-stimulated (c) WT vs. KO neurons. (d) AKT pathway: Immunoblots of phosphorylated AKT (p-AKT(Ser473)), AKT-phosphorylated GSK3 (p-GSK3α(Ser21) top, p-GSK3β(Ser9) bottom, and AKT-phosphorylated β-catenin (p-β-cat(Ser522)), in WT vs. KO neurons. (e-g) Q-PCR for Wnt/β-catenin pathway transcriptional targets in neurons: Axin1 (e) and Axin2 (f); GAPDH (control) (g); KO (black) vs. WT (white). Left, untreated; Middle, transfected with β-cat(S33Y); Right, treated with Wnt3a. (h-j) Neurodevelopmental responses to Wnt/β-catenin pathway stimulation. Quantification (as in Fig 1): (h) spine density, (i) % filopodia and (j) glutamatergic synapse density; white, WT; black, KO, all conditions normalized to WT untreated (left-most bar). Comparisons as in (e-g). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; #p ≤ 0.05 vs. untransfected WT.
Figure 3.
GSK3 inhibition rescues Dixdc1KO phenotypes. (a-b) Pharmacologic rescue of behavioral phenotypes. The FST phenotype (increased time immobile) (a) and SIP phenotype (reduced social interaction) (b) are rescued by injection of either lithium (middle) or GSK3i (right).
(c-g) Pharmacologic rescue of dendritic spine phenotypes. Cortical L5/6 apical dendrites labeled by Tg(Thy1-EGFP)M in mice treated with vehicle (c), lithium (d) or GSK3i (e). Top, WT; bottom, KO; arrows and asterisks as in Fig 1e. Quantification, all conditions normalized to WT vehicle (left-most bar) (f and g).
(h-k) Pharmacologic rescue of glutamatergic synapse phenotypes. Co-localized immunohistochemical markers for glutamatergic synapses on cortical L5/6 apical dendrites labeled by Tg(Thy1-EGFP)M in mice treated with vehicle (h), lithium (i) or GSK3i (j). Top, WT; bottom, KO; colors as in Fig 1r. Quantification with all conditions normalized to WT vehicle (left-most bar) (k).
Scale bars, 5μm. *p ≤0.05; **p ≤0.01; ***p ≤0.001
Figure 4.
Increased rare sequence-disrupting DIXDC1 SNVs in ASD, BD and Scz. (a) Schematic representation of human DIXDC1 isoform 1 and isoform 2. Yellow, calponin homology domain (CH); pink, coiled-coil domain; orange, DIX domain. (b, c) % of individuals carrying a rare sequence-disrupting (nonsense, missense or splice-site disrupting) SNV in DIXDC1 isoform 1 (b) and 2 (c). (d) Relative TOPflash (Wnt/β-catenin signaling) activity for WT human DIXDC1 isoform 1 vs. isoform 2; values normalized to isoform 2 (white bar). ***p ≤0.001
Figure 5.
Rescue and dominant neurodevelopmental effects of missense SNVs with functional effects on the Wnt/β-catenin pathway. (a) Schematic diagram of isoform 2 indicating positions of rare missense SNVs found in ASD (red, top) vs. ethnically matched-controls (blue, bottom) in the discovery (AASC) dataset. (b) TOPflash for alleles shown in (a); values normalized to WT isoform 2 (white bar); alleles grouped as hypoactive, neutral, or hyperactive based on Δ ≥10% vs. WT. (c-e) Neurodevelopmental rescue: WT human DIXDC1 isoform 2 (grey bar) restores spine density (c), % immature spines (d) and glutamatergic synapse density (e) to WT levels (white bar) when expressed in KO neurons. Control-derived SNVs (K89I, C389F) (blue bars) but no case-derived SNVs (red bars), similarly rescue these KO phenotypes. (f-h) Dominant neurodevelopmental effects: WT human DIXDC1 isoform 2 (grey bar) or cDNAs containing hypoactive or activity-neutral SNVs (K89I, C389F, R154T, R249Q, T401M, P285T) do not cause neurodevelopmental phenotypes, but cDNAs containing hyperactive SNVs found in cases (A87T, Q169R, K188N, Q218H, R367W) decrease spine density (f), increase immature spine % (g) and decrease glutamatergic synapse density (h) when overexpressed in WT neurons. *p ≤0.05; **p ≤0.01; ***p ≤0.001 vs. WT in (b-e); ## p ≤0.01; ### p ≤0.001 vs. identical genotype + empty vector in (c-h).